Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness

BACKGROUND: Conventional clinical biomarkers cannot accurately differentiate indolent from aggressive prostate cancer (PCa). We investigated the usefulness of a biomarker panel measured exclusively in biofluids for assessment of PCa aggressiveness. METHODS: We collected biofluid samples (plasma/seru...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Plazas, Xavier, Rodríguez-Gallego, Esther, Alves, Marta, Altuna-Coy, Antonio, Lozano-Bartolomé, Javier, Portero-Otin, Manel, García-Fontgivell, Joan Francesc, Martínez-González, Salomé, Segarra, José, Chacón, Matilde R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734315/
https://www.ncbi.nlm.nih.gov/pubmed/31500625
http://dx.doi.org/10.1186/s12967-019-2053-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734315/
https://www.ncbi.nlm.nih.gov/pubmed/31500625
http://dx.doi.org/10.1186/s12967-019-2053-6

Ejemplares similares